Search clinical trials for: Melanoma Peptide Vaccine

Total 14875 results

Mayo Clinic

Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA)

Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 and other conditions

United States
Fred Hutchinson Cancer Center
Amazon.com Services LLC

Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditions

United States
Inge Marie Svane

Recruiting

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

Metastatic Melanoma

Denmark
National Cancer Institute (NCI)

Completed

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Recurrent Melanoma | Stage IV Melanoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Cancer

Melanoma | Breast Cancer | Colorectal Cancer | Lung Cancer | Bone Cancer | Rectal Cancer | Uterine Sarcoma | Colon Cancer | Ovarian Sarcoma | Eye Cancer | Adult Soft Tissue Sarcoma

United States
Craig L Slingluff, Jr
University of Virginia

Completed

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists (MEL60)

Melanoma | Metastatic Melanoma | Mucosal Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Prometheus Laboratories; Key Biologics, LLC; Adelson...

Active, not recruiting

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Melanoma

United States
Craig L Slingluff, Jr
Celldex Therapeutics

Completed

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (Mel-65)

Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Terminated

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61)

Melanoma

United States
Craig L Slingluff, Jr
Cancer Research Institute, New York City; Ludwig Institute for Cancer Research

Terminated

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma (Mel63; CHAMP)

Melanoma

United States
Craig L Slingluff, Jr
Celldex Therapeutics

Active, not recruiting

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) (Mel66)

Melanoma | Ocular Melanoma | Uveal Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab (Mel64)

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Melanoma (Skin)

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Herlev Hospital

Completed

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Squamous Cell Carcinoma of the Head and Neck | Urothelial Carcinoma | Malignant Melanoma

Denmark
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Melanoma (Skin)

United States
Ludwig Institute for Cancer Research

Terminated

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Malignant Melanoma

Belgium
Ludwig Institute for Cancer Research

Terminated

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Malignant Melanoma

Belgium
Bristol-Myers Squibb
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); University of Southern California; University... and other collaborators

Completed

Study of Gene Modified Immune Cells in Patients With Advanced Melanoma (F5)

Metastatic Melanoma

United States
M.D. Anderson Cancer Center

Completed

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
BioNTech US Inc.
Bristol-Myers Squibb

Completed

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Melanoma | Carcinoma, Non-Small-Cell Lung | Lung Cancer | Urinary Bladder Cancer | Skin Cancer | Transitional Cell Carcinoma of the Bladder | Malignant Melanoma | Bladder Tumors

United States
University of Chicago
Eisai Inc.

Terminated

Vaccination Plus Ontak in Patients With Metastatic Melanoma

Melanoma

United States
Patrick Ott, MD

Completed

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

Melanoma

United States
BioNTech US Inc.
Apexigen, Inc.

Terminated

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Metastatic Melanoma

United States
Jonsson Comprehensive Cancer Center

Completed

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

Melanoma

United States
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH)

Completed

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Mucosal Melanoma | Iris Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Medium/Large Size Posterior Uveal Melanoma | Recurrent... and other conditions

United States
Centre Hospitalier Universitaire Vaudois
Immutep S.A.S.

Terminated

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321)

Melanoma

Switzerland
Craig L Slingluff, Jr

Terminated

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (Mel62; 6PAC)

Melanoma

United States
Xiangya Hospital of Central South University

Unknown

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Melanoma (Skin)

China
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Terminated

Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

Melanoma | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Gastrointestinal Cancer

United States
M.D. Anderson Cancer Center

Completed

Melanoma Vaccine With Peptides and Leuprolide

Melanoma

United States
Walter J. Storkus
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

Metastatic Melanoma

United States
Cliniques universitaires Saint-Luc- Université...

Terminated

Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Metastatic Melanoma

Belgium
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Incyte Corporation; University of Virginia

Completed

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma | Stage IIIA Skin Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma | Recurrent Uveal Melanoma

United States
Craig L Slingluff, Jr

Completed

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma (MEL39)

Melanoma

United States
Inge Marie Svane
Copenhagen University Hospital at Herlev

Terminated

Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients

Malignant Melanoma

Denmark
Ahmad Tarhini
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Intraocular Melanoma | Malignant Conjunctival Neoplasm | Melanoma (Skin)

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

Melanoma

United States
Craig L Slingluff, Jr

Terminated

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma (Mel 51)

Melanoma

United States
University of Virginia

Completed

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma (MEL53)

Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Advanced Melanoma (Mel48)

Intraocular Melanoma | Malignant Conjunctival Neoplasm | Melanoma (Skin)

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI); University of Virginia; Oncovir, Inc.

Completed

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (MEL58)

Melanoma

United States
Rabih Said
Agenus Inc.

Withdrawn

Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

Melanoma

United States

Search clinical trials for: Melanoma Peptide Vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations